Montelukast, a potent leukotriene receptor antagonist, causes dose- related improvements in chronic asthma

European Respiratory Journal

Volumn 11, Issue 6, 1998, Pages 1232-1239

  Noonan, M J ^a   Chervinsky, P ^b   Brandon, M ^c   Zhang, J ^d   Kundu, S ^d   McBurney, J ^d   Reiss, T F ^d  

^a Allergy Associates Research Center   (United States)

^b Allergy Associates Inc   (United States)

^c San Diego Medical Center   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Asthma; Dose response; Leukotriene receptor antagonist; Montelukast

Indexed keywords

LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ACETATES; ADOLESCENT; ADULT; AGED; ASTHMA; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; QUALITY OF LIFE; QUINOLINES; SPIROMETRY;

EID: 0031835681     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.98.11061232     Document Type: Article

References (29)

1. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 1990; 323: 645-655.
2. Weiss JW, Drazen JM, Coles N, et al. Bronchoconstriction effects of leukotriene C in humans. Science 1982; 216: 196-198.
3. Laitinen LA, Laitinen A, Haahtela T, et al. Leukotriene Eg and granulocytic infiltrations into asthmatic airways. Lancet 1993; 341: 989-990.
4. 4. Am J Pathol 1987; 126: 19-24.
5. 4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis 1982; 126: 449-451.
6. Bisgaard H, Pedersen M. SRS-A leukotrienes decrease the activity of human respiratory cilia. Clin Allergy 1987; 17: 95-103.
7. 4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. J Allergy Clin Immunol 1992; 90: 193-201.
8. 4-receptor antagonist. N Engl J Med 1990; 323: 1736-1739.
9. 4) receptor antagonist (MK-0571) in patients with asthma. Am Rev Respir Dis 1992; 146: 358-363.
10. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150(3): 618-623.
11. Israel E, Rubin P, Kemp JP, et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma. Ann Intern Med 1993; 119: 1059-1066.
12. 4 receptor antagonist. Can J Phys Pharm 1995; 73(2): 191-201.
13. 4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 1995; 61(1): 83-92.
14. 4 receptor antagonist, inhibits exercise induced bronchoconstriction in asthmatics at the end of a once daily dosing interval. Am J Respir Crit Care Med 1995; 151: A377.
15. 4 receptor antagonist, improves the signs and symptoms of asthma with a dose as low as 10 mg, once daily. Am J Respir Crit Care Med 1995; 151: A378.
16. Crapo RO, Hankinson JL, Irvin C. Standardization of spirometry. Am J Respir Crit Care Med 1995; 152: 1107-1136.
17. Santanello NC, Barber BL, Reiss TF, et al. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J 1997; 10: 646-651.
18. Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992; 47: 76-83.
19. Tukey JW, Ciminera JL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics 1985; 41: 295-301.
20. Kamada AK, Szefler SJ, Martin RJ, et al. Issues in the use of inhaled glucocorticoids. Am J Respir Crit Care Med 1996; 153: 1739-1748.
21. Boe J, Rosenhall L, Alton M, et al. Comparison of dose-response effects of inhaled beclomethasone diproprionate and budesonide in the management of asthma. Allergy 1989; 44: 349-355.
22. Johansson SA, Dahl R. A double-blind dose-response study of budesonide by inhalation in patients with bronchial asthma. Allergy 1988; 43: 173-178.
23. Toogood JH, Lefcoe NM, Haines DSM, et al. A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. J Allergy Clin Immunol 1977; 58(4): 298-308.
24. Dahl R, Lundback B, Malo J-L, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993; 104(5): 1352-1358.
25. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children: a dose-response study. J Allergy Clin Immunol 1995; 95: 29-33.
26. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharm Ther (in press).
27. Busse WW, Sedgwick JB. Eosinophils in asthma. Ann Allergy 1992; 68(3): 286-290.
28. Evans PM, O'Connor BJ, Fuller RW, Barnes PJ, Chung KF. Effect of inhaled corticosteroids on peripheral blood eosinophil counts and density profiles in asthma. J Allergy Clin Immunol 1993; 91: 643-650.
29. 4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98: 528-534.